Abstract:Abstract Background Depression is highly related to Alzheimer’s disease (AD), yet no effective treatment is available. Phosphodiesterase-4 (PDE4) has been considered a promising target for treatment of AD and depression. Roflumilast, the first PDE4 inhibitor approved for clinical use, improves cognition at doses that do not cause side effects such as emesis. Methods Here we examined the effects of roflumilast on behavioral dysfunction and the related mechanisms in APPswe/PS1dE9 transgenic mice, a widely used model of AD. Mice at 10 months of age were examined for memory in the novel object recognition and Morris water-maze tests and depression-like behavior in the tail-suspension test and forced swimming test before killing for neurochemical assays. Results In the novel object recognition and Morris water-maze, APPswe/PS1dE9 mice showed significant cognitive declines, which were reversed by roflumilast at 5 and 10 mg/kg orally once per day. In the tail-suspension test and forced swimming test, the AD mice showed prolonged immobility time, which was also reversed by roflumilast. In addition, the staining of hematoxylin–eosin and Nissl showed that roflumilast relieved the neuronal cell injuries, while terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling analysis indicated that roflumilast ameliorated cell apoptosis in AD mice. Further, roflumilast reversed the decreased ratio of B-cell lymphoma-2/Bcl-2-associated X protein and the increased expression of PDE4B and PDE4D in the cerebral cortex and hippocampus of AD mice. Finally, roflumilast reversed the decreased levels of cyclic AMP (cAMP) and expression of phosphorylated cAMP response element-binding protein and brain derived neurotrophic factor in AD mice. Conclusions Together, these results suggest that roflumilast not only improves learning and memory but also attenuates depression-like behavior in AD mice, likely via PDE4B/PDE4D-mediated cAMP/cAMP response element-binding protein/brain derived neurotrophic factor signaling. Roflumilast can be a therapeutic agent for AD, in particular the comorbidity of memory loss and depression.

Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme

Interaction Between the Antidepressant-Like Behavioral Effects of Beta Adrenergic Agonists and the Cyclic AMP PDE Inhibitor Rolipram in Rats

Antidepressant-like Effects of PDE4 Inhibitors Mediated by the High-Affinity Rolipram Binding State (HARBS) of the Phosphodiesterase-4 Enzyme (PDE4) in Rats.

Antidepressant- and Anxiolytic-Like Effects of the Phosphodiesterase-4 Inhibitor Rolipram on Behavior Depend on Cyclic AMP Response Element Binding Protein-Mediated Neurogenesis in the Hippocampus.

Effects of Repeated Treatment with Phosphodiesterase-4 Inhibitors on Camp Signaling, Hippocampal Cell Proliferation, and Behavior in the Forced-Swim Test

Effects of PDE4 pathway inhibition in rat experimental stroke.

Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B)

Phosphodiesterase-4d Knock-Out And Rna Interference-Mediated Knock-Down Enhance Memory And Increase Hippocampal Neurogenesis Via Increased Camp Signaling

Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior

Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus

Behavioral phenotype of phosphodiesterase 4A (PDE4A) knockout mice suggests a role in memory and anxiety

Inhibition Of Phosphodiesterase-4 Reverses Memory Deficits Produced By A Beta 25-35 Or A Beta 1-40 Peptide In Rats

Inhibition of phosphodiesterase-4 suppresses HMGB1/RAGE signaling pathway and NLRP3 inflammasome activation in mice exposed to chronic unpredictable mild stress

The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats.

MiR-139-5p has an antidepressant-like effect by targeting phosphodiesterase 4D to activate the cAMP/PKA/CREB signaling pathway

Phosphodiesterase genes and antidepressant treatment response: a review.

The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice

Resolvin D1 and D2 Reverse Lipopolysaccharide-Induced Depression-Like Behaviors Through the mTORC1 Signaling Pathway

Effect of Phosphodiesterase‐4 Inhibitor Rolipram on Colonic Hypermotility in Water Avoidance Stress Rat Model

Rolipram, a PDE4 Inhibitor, Enhances the Inotropic Effect of Rat Heart by Activating SERCA2a.